Market Overview

UPDATE: Goldman Sachs Upgrades Bruker Corporation to Buy on Operational Improvements

Share:
Related BRKR
Bruker Corp Has 'Great Story,' But It's Not Time To Jump In Yet
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research
Bruker (BRKR) Frank H. Laukien on Q4 2015 Results - Earnings Call Transcript (Seeking Alpha)

Goldman Sachs raised its rating on Bruker Corporation (NASDAQ: BRKR) from Neutral to Buy and raised its price target from $13 to $19.

Goldman Sachs commented, "We upgrade shares of Bruker (BRKR) to Buy from Neutral and raise our 12-month price target to $19 (from $13), which implies 40% upside. After underperforming Tools peers by 1000bp YTD, we see a turnaround story for 2013 with healthy organic growth, margin expansion, and an attractive risk/reward profile coupled with the following catalysts: (1) better-than-expected strength in core end markets, (2) pending detail on long-term margin expansion plans, and (3) low expectations/valuation that sets up a “laggards to leader” trade."

Bruker Corporation closed at $13.61 on Friday.

Latest Ratings for BRKR

DateFirmActionFromTo
Feb 2016Deutsche BankMaintainsHold
Jan 2016Cantor FitzgeraldUpgradesHoldBuy
Jan 2016Deutsche BankInitiates Coverage onHold

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (BRKR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters